Cargando…
Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway
Toxicity and the development of resistance by cancer cells are impediments for docetaxel (DTX), a primary drug for treating prostate cancer (PCa). Since the combination of DTX with natural compounds can increase its effectiveness by reducing its toxic concentrations, we evaluated a combination of th...
Autores principales: | Singh, Santosh Kumar, Apata, Tejumola, Gordetsky, Jennifer B., Singh, Rajesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770702/ https://www.ncbi.nlm.nih.gov/pubmed/31540423 http://dx.doi.org/10.3390/cancers11091390 |
Ejemplares similares
-
Clinical Implication of Metformin in Relation to Diabetes Mellitus and Ovarian Cancer
por: Singh, Santosh Kumar, et al.
Publicado: (2021) -
Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
por: Singh, Santosh Kumar, et al.
Publicado: (2020) -
Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
por: Lu, Xinxing, et al.
Publicado: (2020) -
PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
por: Karim, Shahid, et al.
Publicado: (2022) -
Thymoquinone Inhibits JAK/STAT and PI3K/Akt/ mTOR Signaling Pathways in MV4-11 and K562 Myeloid Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2022)